The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Astellas Pharma
EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi
Consulting or Advisory Role - Agensys
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
 
Peter H. O'Donnell
Stock and Other Ownership Interests - Allergan
Honoraria - Algeta ASA; American Medical Forum; Astellas Pharma; AstraZeneca; Genentech/Roche; Harrison Consulting Group; Inovio Pharmaceuticals; Janssen Biotech; Kantar Health; Merck; Novartis; Parexel; Quintiles; Seagen; Xcenda
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Named as co-inventor on a pending patent for a genomic prescribing system for medication prescribing.
Expert Testimony - TERA; Triage Cancer
Travel, Accommodations, Expenses - Merck
Other Relationship - Advance Medical
 
Noah M. Hahn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst)
 
Arjun Vasant Balar
Honoraria - Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Cerulean Pharma; Genentech/Roche; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen
 
Elaina M. Gartner
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Research Funding - Agensys; Astellas Pharma; Seagen
Travel, Accommodations, Expenses - Seagen
 
Amal Melhem-Bertrandt
No Relationships to Disclose
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi